|
||||||||||||||||
| HUM-MOLGEN -> Events -> Meetings and Conferences | ||||||||||||||||
| Engineered Antibody Techhologies Accelerating Drug Discovery & Development | ||||||||||||||||
| July 30, 2001 | ||||||||||||||||
|
Strategic Research Institute, The Park Hyatt at the Bellevue Hotel - Philadelphia, PA September 18-19, 2001 Organized into Four Sections: Post-Genomic HTP Antibody R&D Novel Targets & Selection MAb Generation Pre-Clinical/Clinical Progress NEW! Xenomax Technology: A Highly Efficient System for Generating Fully Human Antibodies Burgeoning New Opportunities in the Monoclonal Antibody Marketplace Mylotarg, an Anti-CD33 Calicheamicin Antibody Conjugate for Treatment of AML Rituxan: Treatment of Lymphoma Millennium's Rapid Antibody Development Systems |
||||||||||||||||
| Organized by: | Strategic Research Institute | |||||||||||||||
| Invited Speakers: | Abgenix Amgen Biosite Centocor Eli Lilly & Company Epicyte Pharmaceuticals Genentech GlaxoSmithKline ICOS Corporation IDEC Pharmaceuticals ImClone Systems Medarex Millennium Pharmaceuticals Wyeth-Ayerst |
|||||||||||||||
| Deadline for Abstracts: | For 2002 Meeting: March 15, 2002 Contact Glenn Pascual at 212-967-0095, ext .245 or email below. | |||||||||||||||
| Registration: | Call Customer Service at 646-336-7030 or 888-666-8514 and mention conference code CS179 | |||||||||||||||
| E-mail: | gpascual@srinstitute.com | |||||||||||||||
| Posted by: | Glenn A. Pascual - conference organizer | |||||||||||||||
| Host: | 12.3.58.15 | |||||||||||||||
|
||||||||||||||||
|
Generated by meetings and positions 5.0 by Kai Garlipp |
||||||||||||||||